Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Colon cancer-associated transcript 1 (CCAT1) was identified as an oncogenic long non-coding RNA (lncRNA) in a variety of cancers. However, there was a lack of understanding of the mechanism by which CCAT1 conferred cisplatin (also known as DDP) resistance in ovarian cancer cells. Materials and Methods Cell viability of A2780, SKOV3, A2780/DDP, and SKOV3/DDP cells upon cisplatin treatment was monitored by MTT assay. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) detected the expression levels of CCAT1 and miR-454. The effect of sh-CCAT1 on cisplatin response was investigated in xenografts study. Bioinformatic analysis, luciferase reporter assay and qRT-PCR were conducted to validate the direct interaction among CCAT1, miR-454, and survivin. Apoptosis was determined by flow cytometry after dual staining of Annexin-V-FITC/propidium iodide, and the expression of apoptosis-related proteins Bcl-2, Bax and survivin were detected by qRT-PCR and Western blotting. Xenograft study was conducted to monitor in vivo tumor formation. Results CCAT1 was highly expressed in cisplatin-resistant ovarian cancer cell line A2780/DDP and SKOV3/DDP. Knockdown of CCAT1 restored sensitivity to cisplatin in vitro and in vivo. Our data revealed that silencing of CCAT1 promoted cisplatin-induced apoptosis via modulating the expression of pro- or anti-apoptotic proteins Bax, Bcl-2, and survivin. CCAT1 directly interacted with miR-454, and miR-454 overexpression potentiated cisplatin-induced apoptosis. Survivin was identified as a functional target of miR-454, restoration of survivin attenuated the effect of miR-454 on cisplatin response. In addition, miR-454 inhibitor or overexpression of survivin was found to abolish sh-CCAT1–induced apoptosis upon cisplatin treatment. Conclusion CCAT1/miR-454/survivin axis conferred cisplatin resistance in ovarian cancer cells.
Abstract
Purpose Colon cancer-associated transcript 1 (CCAT1) was identified as an oncogenic long non-coding RNA (lncRNA) in a variety of cancers. However, there was a lack of understanding of the mechanism by which CCAT1 conferred cisplatin (also known as DDP) resistance in ovarian cancer cells. Materials and Methods Cell viability of A2780, SKOV3, A2780/DDP, and SKOV3/DDP cells upon cisplatin treatment was monitored by MTT assay. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) detected the expression levels of CCAT1 and miR-454. The effect of sh-CCAT1 on cisplatin response was investigated in xenografts study. Bioinformatic analysis, luciferase reporter assay and qRT-PCR were conducted to validate the direct interaction among CCAT1, miR-454, and survivin. Apoptosis was determined by flow cytometry after dual staining of Annexin-V-FITC/propidium iodide, and the expression of apoptosis-related proteins Bcl-2, Bax and survivin were detected by qRT-PCR and Western blotting. Xenograft study was conducted to monitor in vivo tumor formation. Results CCAT1 was highly expressed in cisplatin-resistant ovarian cancer cell line A2780/DDP and SKOV3/DDP. Knockdown of CCAT1 restored sensitivity to cisplatin in vitro and in vivo. Our data revealed that silencing of CCAT1 promoted cisplatin-induced apoptosis via modulating the expression of pro- or anti-apoptotic proteins Bax, Bcl-2, and survivin. CCAT1 directly interacted with miR-454, and miR-454 overexpression potentiated cisplatin-induced apoptosis. Survivin was identified as a functional target of miR-454, restoration of survivin attenuated the effect of miR-454 on cisplatin response. In addition, miR-454 inhibitor or overexpression of survivin was found to abolish sh-CCAT1–induced apoptosis upon cisplatin treatment. Conclusion CCAT1/miR-454/survivin axis conferred cisplatin resistance in ovarian cancer cells.
참고문헌 (29)
- Siegel RL, "Cancer statistics, 2017", CA Cancer J Clin, 67, pp.7~30 (2017)
- Xiyi Jiang, "Epidemiology of gynecologic cancers in China", Journal of Gynecologic Oncology, 29(1), pp.1~7 (2018), 대한부인종양학회[DOI]
- Oronsky B, "A brief review of the management of platinum-resistantplatinum-refractory ovarian cancer", Med Oncol, 34, pp.103~ (2017)
- Nikpayam E, "The role of long non-coding RNAs in ovarian cancer", Iran Biomed J, 21, pp.3~15 (2017)
- Vergote I, "Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer", N Engl J Med, 363, pp.943~953 (2010)
- Fatica A, "Long non-coding RNAs : new players in cell differentiation and development", Nat Rev Genet, 15, pp.7~21 (2014)
- Chen J, "Long noncoding RNA CCAT1 acts as an oncogene and promotes chemoresistance in docetaxel-resistant lung adenocarcinoma cells", Oncotarget, 7, pp.62474~62489 (2016)
- Nissan A, "Colon cancer associated transcript-1 : a novel RNA expressed in malignant and pre-malig-nant human tissues", Int J Cancer, 130, pp.1598~1606 (2012)
- Deng L, "Long noncoding RNA CCAT1 promotes hepatocellular carcinoma progression by functioning as let-7 sponge", J Exp Clin Cancer Res, 34, pp.18~ (2015)
- Ma MZ, "Long non-coding RNA CCAT1 promotes gallbladder cancer development via negative modulation of miRNA-218-5p", Cell Death Dis, 6, pp.e1583~ (2015)
- Liu SP, "Identification of differentially expressed long non-coding RNAs in human ovarian cancer cells with different metastatic potentials", Cancer Biol Med, 10, pp.138~141 (2013)
- Wang Q, "LncRNA CCAT1 modulates the sensitivity of paclitaxel in nasopharynx cancers cells via miR-181a", CPEB2 axis, 2017, pp.16, 795~801
- Yang X, "Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer", J Cancer Res Clin Oncol, 130, pp.423~428 (2004)
- Salmena L, "A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?", Cell, 146, pp.353~358 (2011)
- Wang S, "Elevated expression of erbB3confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin", Oncogene, 29, pp.4225~4236 (2010)
- Zhong Y, "Dysregulated expression of long noncoding RNAs in ovarian cancer", Int J Gynecol Cancer, 26, pp.1564~1570 (2016)
- Lai XJ, "LncRNA colon cancer-associated transcript 1(CCAT1)promotes proliferation and metastasis of ovarian cancer via miR-1290", Eur Rev Med Pharmacol Sci, 22, pp.322~328 (2018)
- Inoue S, "Apoptosis and anticancer drug resistance", Hum Cell, 14, pp.211~221 (2001)
- Helm CW, "Enhancing the efficacy of cisplatin in ovarian cancer treatment-could arsenic have a role", J Ovarian Res, 2, pp.2~ (2009)
- Fraser M, "Chemoresistance in human ovarian cancer : the role of apoptotic regulators", Reprod Biol Endocrinol, 1, pp.66~ (2003)
- Hu B, "LncRNA CCAT1", miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4, 2017, pp.18, 974~983
- Liang HL, "MiR-454prompts cell proliferation of human colorectal cancer cells by repressing CYLD expression", Asian Pac J Cancer Prev, 16, pp.2397~2402 (2015)
- Zhou L, "Involvement of miR-454overexpression in the poor prognosis of hepatocellular carcinoma", Eur Rev Med Pharmacol Sci, 20, pp.825~829 (2016)
- Li Q, "MicroRNA-454 may function as an oncogene via targeting AKT in triple negative breast cancer", J Biol Res(Thessalon), 24, pp.10~ (2017)
- Wang X, "MicroRNA-454 inhibits the malignant biological behaviours of gastric cancer cells by directly targeting mitogen-activated protein kinase 1", Oncol Rep, 39, pp.1494~1504 (2018)
- Zhao X, "LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p", Stat3, 2018, pp.109, 3068~3079
- Chen X, "Survivin and tumorigenesis : molecular mechanisms and therapeutic strategies", J Cancer, 7, pp.314~323 (2016)
- Xu Y, "Dihydromyricetin induces apoptosis and reverses drug resistance in ovarian cancer cells by p53-mediated downregulation of survivin", Sci Rep, 7, pp.46060~ (2017)
- Chen Q, "Smac combined with DDP can inhibit drug resistance of ovarian cancer through regulation of Survivin expression", Cancer Biomark, 22, pp.1~6 (2018)